AM-928 infusion safety study for advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent to join the study
- You have an advanced solid tumor cancer that cannot be surgically removed or has spread, and standard treatments haven’t worked for you
- You have tumor tissue available from a past biopsy or diagnosis, so the lab can test it
- Your scans show at least one measurable tumor spot, and you’re well enough to do daily activities most of the time (ECOG 0–2)
- Your blood, liver, kidney, and clotting tests meet the study thresholds
- You have at least 12 weeks to live, and you can follow study visits and instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
This trial tests a new drug, A-337, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if A-337 is safe and effective, and to find the right dose.
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.